Faricimab Injection [Vabysmo]

DRUG7 trials

Sponsors

Association for Innovation and Biomedical Research on Light and Image, Hospital Authority, Hong Kong, Rigshospitalet, Denmark, Junyeop Lee, Yeungnam University College of Medicine

Conditions

Age Related Macular DegenerationDiabetic Retinopathy, DRIntraocular InflammationMacular DegenerationMacular Degeneration Choroidal NeovascularizationNeovascular Age-Related Macular Degeneration (nAMD)Polypoidal Choroidal VasculopathyPolypoidal Choroidal Vasculopathy (PCV)

Phase 3

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

RecruitingNCT07461441

Yeungnam University College of MedicineAge Related Macular Degeneration, Polypoidal Choroidal Vasculopathy (PCV)

Start: 2026-03-01End: 2028-11-30Target: 50Updated: 2026-03-10

Phase 4

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

RecruitingNCT06709339

Association for Innovation and Biomedical Research on Light and ImagePolypoidal Choroidal Vasculopathy

Start: 2025-08-06End: 2028-08-01Target: 120Updated: 2026-02-06

Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration

RecruitingNCT06742307

Hospital Authority, Hong KongMacular Degeneration Choroidal Neovascularization

Start: 2025-08-21End: 2027-02-01Target: 40Updated: 2025-10-01

Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration

Not yet recruitingNCT07367282

Junyeop LeeMacular Degeneration

Start: 2026-04-01End: 2028-12-31Target: 64Updated: 2026-01-27

Unknown Phase

Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration

CompletedNCT06890026

Rigshospitalet, DenmarkNeovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve

Start: 2024-11-15End: 2026-03-01Updated: 2026-03-27

Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy

CompletedNCT06902207

Rigshospitalet, DenmarkIntraocular Inflammation

Start: 2024-11-10End: 2025-03-01Updated: 2025-03-30

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

CompletedNCT07526857

Federico II UniversityDiabetic Retinopathy, DR

Start: 2025-01-01End: 2026-01-01Updated: 2026-04-13

Related Papers

Real-world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study.

2026-05-16

Durability of Three Monthly Loading Doses with Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration

Ophthalmology and Therapy2026-05-09